NASDAQ:CTSOCytosorbents Stock Price, Forecast & News

$9.73

-0.80 (-7.60 %)

(As of 05/27/2020 04:00 PM ET)

Add

Compare

Today's Range

$9.42

Now: $9.73▼

$10.80

50-Day Range

$6.28

MA: $9.00▼

$10.59

52-Week Range

$3.49

Now: $9.73▼

$11.24

Volume1.10 million shs

Average Volume770,421 shs

Market Capitalization$352.53 million

P/E RatioN/A

Dividend YieldN/A

Beta0.52

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; K+ontrol, a development stage blood purification technology; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Cytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.25, Cytosorbents has a potential upside of 56.7% from its current price of $9.73.
Amount of Analyst Coverage
Cytosorbents has only been the subject of 4 research reports in the past 90 days.

3.5 Community Rank

Outperform Votes
Cytosorbents has received 418 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Cytosorbents has received 178 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Cytosorbents has received 70.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote “Outperform” if you believe CTSO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Cytosorbents does not currently pay a dividend.
Dividend Growth
Cytosorbents does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cytosorbents insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $128,062.00 in company stock.
Percentage Held by Insiders
Only 5.60% of the stock of Cytosorbents is held by insiders.
Percentage Held by Institutions
Only 27.54% of the stock of Cytosorbents is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Cytosorbents are expected to grow in the coming year, from ($0.39) to ($0.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cytosorbents is -17.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cytosorbents is -17.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cytosorbents has a P/B Ratio of 16.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical & medical instruments

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CTSO

Previous Symbol

CUSIPN/A

CIK1175151

Webwww.cytosorbents.com

Phone732-329-8885

Debt

Debt-to-Equity Ratio0.54

Current Ratio3.27

Quick Ratio3.10

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$24.95 million

Price / Sales14.13

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.59 per share

Price / Book16.49

Profitability

EPS (Most Recent Fiscal Year)($0.60)

Net Income$-19,270,000.00

Net Margins-62.65%

Return on Equity-165.86%

Return on Assets-55.40%

Miscellaneous

Employees125

Outstanding Shares36,231,000

Market Cap$352.53 million

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive CTSO News and Ratings via Email

Sign-up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.

Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions

How has Cytosorbents' stock been impacted by COVID-19 (Coronavirus)?

Cytosorbents' stock was trading at $4.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTSO shares have increased by 104.0% and is now trading at $9.73. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cytosorbents?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cytosorbents.

When is Cytosorbents' next earnings date?

Cytosorbents is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Cytosorbents.

How were Cytosorbents' earnings last quarter?

Cytosorbents Corp (NASDAQ:CTSO) posted its earnings results on Tuesday, May, 5th. The medical research company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.04. The medical research company had revenue of $8.71 million for the quarter, compared to analysts' expectations of $7.14 million. Cytosorbents had a negative net margin of 62.65% and a negative return on equity of 165.86%. View Cytosorbents' earnings history.

What price target have analysts set for CTSO?

4 brokers have issued 12-month price targets for Cytosorbents' stock. Their forecasts range from $14.00 to $17.00. On average, they anticipate Cytosorbents' stock price to reach $15.25 in the next twelve months. This suggests a possible upside of 56.7% from the stock's current price. View analysts' price targets for Cytosorbents.

Has Cytosorbents been receiving favorable news coverage?

Press coverage about CTSO stock has trended somewhat positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytosorbents earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news aboutCytosorbents.

Who are some of Cytosorbents' key competitors?

Some companies that are related to Cytosorbents include Cantel Medical (CMD), Luminex (LMNX), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX), Cardiovascular Systems (CSII), Silk Road Medical (SILK), Atrion (ATRI), Cerus (CERS), Tactile Systems Technology (TCMD), Cryolife (CRY), Orthopediatrics (KIDS), OraSure Technologies (OSUR), Orthofix Medical (OFIX), GenMark Diagnostics (GNMK) and Vapotherm (VAPO). View all competitors.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include NanoViricides (NNVC), Rekor Systems (REKR), Alibaba Group (BABA), Advanced Micro Devices (AMD), Micron Technology (MU), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE) and AbbVie (ABBV).

Who are Cytosorbents' key executives?

Cytosorbents' management team includes the following people:

Dr. Phillip P. Chan, CEO, Pres & Director (Age 49)
Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 64)
Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 61)
Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 80)

What is Cytosorbents' stock symbol?

Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.79%), Skylands Capital LLC (3.11%), Granahan Investment Management Inc. MA (1.91%), State Street Corp (1.49%), Sargent Investment Group LLC (1.30%) and Geode Capital Management LLC (1.17%). Company insiders that own Cytosorbents stock include Al Kraus, Kathleen P Bloch, Phillip P Chan and Vincent Capponi. View institutional ownership trends for Cytosorbents.

Which institutional investors are selling Cytosorbents stock?

CTSO stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, JPMorgan Chase & Co., Two Sigma Advisers LP, UBS Group AG, State Street Corp, Victory Capital Management Inc., Victory Capital Management Inc., and Creative Planning. View insider buying and selling activity for Cytosorbents.

Which institutional investors are buying Cytosorbents stock?

CTSO stock was acquired by a variety of institutional investors in the last quarter, including Skylands Capital LLC, Sargent Investment Group LLC, EAM Investors LLC, Raymond James & Associates, Soleus Capital Management L.P., Geode Capital Management LLC, EAM Global Investors LLC, and Advisor Group Holdings Inc.. Company insiders that have bought Cytosorbents stock in the last two years include Kathleen P Bloch, and Phillip P Chan. View insider buying and selling activity for Cytosorbents.

How do I buy shares of Cytosorbents?

Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytosorbents' stock price today?

One share of CTSO stock can currently be purchased for approximately $9.73.

How big of a company is Cytosorbents?

Cytosorbents has a market capitalization of $352.53 million and generates $24.95 million in revenue each year. The medical research company earns $-19,270,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. Cytosorbents employs 125 workers across the globe.

What is Cytosorbents' official website?

The official website for Cytosorbents is www.cytosorbents.com.

How can I contact Cytosorbents?

Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff